Virginia and D.K. Ludwig Professor of Medicine, Harvard Medical School
Oncology
Dr. Lee M. Nadler, MD
|
|
Give Review
Nadler works in the field of Oncology. He researched medicine at Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School has a rank of 1 in research and a 12 in primary care He received awards:"Elected Member" and "Super Doctor". Nadler is a published physician. He has 44 publications published. The most current publication "IL-21 Can Supplement Suboptimal Lck-Independent MAPK Activation in a STAT-3-Dependent Manner in Human CD8+ T Cells."
Publications
- IL-21 Can Supplement Suboptimal Lck-Independent MAPK Activation in a STAT-3-Dependent Manner in Human CD8+ T Cells.
- Induction of HLA-DP4-restricted anti-Survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
- Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.
- Aberrant Expression of Functional BAFF-System Receptors by Malignant B-Cell Precursors Impacts Leukemia Cell Survival.
- Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade.
- Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.
- Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation.
- Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy.
- Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.
- Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity.
- Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.
- CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.
- Identification of an evolutionarily conserved transcriptional signature of CD8 memory differentiation that is shared by T and B cells.
- Lee Marshall Nadler, MD: a conversation with the editor.
- Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.
- Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
- Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia.
- Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.
- CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants.
- Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.
- Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.
- Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.
- Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.
- Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.
- Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients...
- Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.
- Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.
- Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non...
- Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene exp...
- Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
- pH-triggered microparticles for peptide vaccination.
- Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cell...
- IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.
- Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
- Autoantibodies frequently detected in patients with aplastic anemia.
- The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells.
- Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification.
- MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients.
- cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression.
- HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.
- Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinica...
- CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.
- Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses.
Schools
Harvard Medical School
Columbia Presbyterian Hospital Ny
Columbia Presbyn Hospital
Dana Farber Cancer Institute
DanaFarber Cancer Institute Senior Vice President Experimental Medicine
Doctors Specialties
- Internal Medicine
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Elected Member
- Super Doctor
Education
-
New York Presbyterian Hospital - Columbia Campus -
Harvard Medical School
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Inga T. Lennes, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barrett J. Rollins, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Elizabeth I. Buchbinder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren C. Harshman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew J. Yee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alyssa A. Perez, MD |
|
|
Dr. Timothy G. Ferris, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Yung H. Chyung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen L. Amorim Bernstein, MD |
|
|
Dr. Harry L. Shapiro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy E. McAlindon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ken S. Zaner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren J. Oshry, MD
This Doctor is OpenDoctor Recommended.
|